title: Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis.
abstract: BACKGROUND
  we performed a systematic review and meta-analysis of mucocutaneous toxicities associatedwith sunitinib, an oral multi-tyrosine kinase inhibitor.
  
  
  METHODS
  eligible studies included randomized Phase II and III trials of patients with solid tumors on sunitinib daily, describing events of hand-foot syndrome, skin rash, stomatitis, and skin and hair discoloration.
  
  
  RESULTS
  the relative risk (RR) of all-grade hand-foot skin reaction, skin rash, stomatitis, skin and hair discoloration were 2.12 (95% CI: 1.28-3.51; p < 0.004), 1.33 (95% CI: 1.15-1.54; p < 0.0002), 1.88 (95% CI: 1.36-2.59; p = 0.0001), 16.6 (95% CI: 4.18-64.94 p < 0.003), 4.42 (95% CI: 0.8-24.5; p < 0.09); respectively.
  
  
  CONCLUSIONS
  our meta-analysis has demonstrated that sunitinib is associated with a higher risk of developing all-grade hand-foot skin reaction, skin rash, stomatitis and skin discoloration compared with control. Clinicians should be aware of these risks and perform regular clinical monitoring.
authors.affiliation: Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
authors.forename: Omar
authors.initials: O
authors.lastname: Abdel-Rahman
authors.forename: Mona
authors.initials: M
authors.lastname: Fouad
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D003875:Drug Eruptions; D060831:Hand-Foot Syndrome / Q000209:etiology; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D052016:Mucositis / Q000139:chemically induced; D011758:Pyrroles / Q000009:adverse effects*; D000077210:Sunitinib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib
keywords: hand–foot skin reaction; meta-analysis; mucocutaneous toxicities; skin rash; stomatitis; sunitinib; tyrosine kinase inhibitors.